Predictors for the Treatment Effect of Sodium Glucose Co-transporter 2 Inhibitors in Patients with Type 2 Diabetes Mellitus

Salim, Hotimah Masdan and et. al, . (2018) Predictors for the Treatment Effect of Sodium Glucose Co-transporter 2 Inhibitors in Patients with Type 2 Diabetes Mellitus. Advances in Therapy, 35 (1). pp. 124-134. ISSN 0741-238X

[img]
Preview
PDF
Predictors for the Treatment Effect of Sodium Glucose Co-transporter 2 Inhibitors in Patients with Type 2 Diabetes Mellitus.pdf

Download (837kB) | Preview
[img]
Preview
PDF
peer review.pdf

Download (1MB) | Preview
[img]
Preview
PDF
turnitin.pdf

Download (4MB) | Preview
Official URL: https://link.springer.com/article/10.1007/s12325-0...

Abstract

Introduction Predictors for the effect of sodium glucose co-transporter 2 (SGLT2) inhibitors at lowering hemoglobin A1c (HbA1c) levels in type 2 diabetes mellitus patients remain unclear. We therefore aimed to elucidate these predictors in type 2 diabetes patients after 3 months of SGLT2 treatment. Methods A total of 302 consecutive type 2 diabetes patients who had been treated with SGLT2 inhibitors as monotherapy or add-on therapy to existing antidiabetic treatments were enrolled retrospectively. After excluding 27 patients whose HbA1c levels could not be evaluated 3 months after treatment, the glucose-lowering effects of SGLT2 inhibitors were assessed in 275 patients by measuring HbA1c levels before and 3 months after treatment. The predictors for changes in HbA1c levels after 3 months of treatment were evaluated. Results SGLT2 inhibitor treatment for 3 months decreased HbA1c levels from 7.8 ± 1.2% to 7.4 ± 1.0% (p < 0.0001). A multiple regression analysis showed that the independent determinants for SGLT2 inhibitor treatment effect included decreased HbA1c levels after 1 month of treatment, high baseline HbA1c levels, and a high estimated glomerular filtration rate (eGFR). Conclusion We show that type 2 diabetes patients who received the greatest glucose-lowering effect with SGLT2 inhibitor treatment were those with preserved renal function (high baseline eGFR) and high baseline HbA1c levels. Moreover, SGLT2 inhibitor treatment efficacy could be predicted by the patients’ initial response to treatment.

Item Type: Article
Uncontrolled Keywords: Estimated glomerular filtration rate, Glucose-lowering, HbA1c ,Predictors, Type 2 diabetes mellitus
Subjects: R Medicine > RC Internal medicine > RC581-951 Specialties of internal medicine
Divisions: Faculty of Medicine > Program Study of Medicine
Depositing User: Mr. . Aji
Date Deposited: 20 Mar 2019 04:46
Last Modified: 27 Mar 2019 01:26
URI: http://repository.unusa.ac.id/id/eprint/3832

Actions (login required)

View Item View Item